ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 15.2% on Thursday . The company traded as low as GBX 2.30 ($0.03) and last traded at GBX 2.46 ($0.03). 4,418,779 shares were traded during trading, a decline of 82% from the average session volume of 24,563,990 shares. The stock had previously closed at GBX 2.90 ($0.04).
ImmuPharma Trading Up 27.6 %
The firm has a market cap of £13.95 million, a price-to-earnings ratio of -335.00 and a beta of 1.53. The firm’s 50-day moving average is GBX 1.59 and its 200-day moving average is GBX 1.69.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- How to Effectively Use the MarketBeat Ratings Screener
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- How to trade using analyst ratings
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Using the MarketBeat Dividend Tax Calculator
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
